Data from an integrated genomic profiling of 218 prostate tumors by Taylor et al. revealed that Spry1 and Spry2 genes are inactivated in 15 and 18 % of the primary cancer, as well as in 42 and 74 % of the metastatic disease, respectively [148]. This evidence concerns the gene SPRY2 and cancer.